drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An antibody–drug conjugate comprising an anti-HER3 monoclonal antibody linked to the topoisomerase I inhibitor DXd; binds HER3 (ERBB3), internalizes, and releases DXd to induce DNA damage with potential bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
patritumab deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-HER3 (ERBB3) antibody–drug conjugate; binds HER3 on tumor cells, is internalized, and releases the topoisomerase I inhibitor DXd via a cleavable linker, causing DNA damage/topoisomerase I inhibition and cytotoxicity with a membrane-permeable bystander effect.
drug_name
Patritumab deruxtecan (HER3-DXd; U3-1402)
nct_id_drug_ref
NCT06298084